about
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trialsThe tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD miceFate of lymphocytes after withdrawal of tofacitinib treatmentNOX3 NADPH oxidase couples transient receptor potential vanilloid 1 to signal transducer and activator of transcription 1-mediated inflammation and hearing lossA flow cytometry technique to study intracellular signals NF-kappaB and STAT3 in peripheral blood mononuclear cells.Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility.A role for IL-27p28 as an antagonist of gp130-mediated signaling.Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis.Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatmentJanus kinase 3: the controller and the controlledA mechanism underlying NOTCH-induced and ubiquitin-mediated JAK3 degradation.Introduction to immune cell signalling.A Role for PPARgamma in the Regulation of Cytokines in Immune Cells and Cancer.The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.Current and potential immune therapies and vaccines in the management of psoriasis.The role of JAK-3 in regulating TLR-mediated inflammatory cytokine production in innate immune cells.JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokinesIntracellular signaling mechanisms associated with CD47 modified surfaces.Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis.Emerging immunotherapies for rheumatoid arthritis.JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.Immunotargeting in the management of psoriasis.Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis.
P2860
Q28084309-ED43AEA8-5201-4692-B794-85C4D369F5BAQ28483660-E2D4AED9-5027-4474-BDBA-5956A29DB0EBQ28538586-882C0334-4CED-41A7-B846-C4B8053C4692Q30469563-FCEC0AE4-7772-44E5-907B-4DF10C38F9CAQ33292504-7BF90E7C-94F3-427A-B94E-5DA0C6F215D5Q33790356-0CFF0669-4BCF-4E92-9DF8-07026F76B8D0Q34688139-28B41CF8-CB8B-45F5-A8AF-2E39E58BFB4EQ35620368-88FFAB50-3E0E-4E18-86B5-995C3A11FB01Q35636761-F09BEA14-6CBD-4A42-9256-4E3DE6669DE7Q35638554-48687C1D-A8F6-4F11-A2D8-8DFCCBBCD095Q35770946-88009A47-15BF-4B85-BA60-23F889D809A2Q35842064-B59883B6-E7E4-4656-B961-44CDEBAC63A7Q36310938-022CC96D-78D8-46FE-988C-50C18EE5A72DQ36724717-1A67538B-9F38-4D93-A51D-EFA075CE2EB7Q36761926-D121BB80-AA15-4605-BE81-CA18D9FE53C1Q36977772-90EB230E-3CB7-4D3D-9420-E03729955F28Q37039005-82DBFBF8-96CF-404F-B5D8-B4EF45D2648BQ37148745-E9FB4F38-6975-4E0C-A0AB-85B1DB1242FFQ37244592-3CD530F2-F8A0-4AA5-8339-4EAAFF9F140EQ38181051-A94002E8-1DA3-4525-972D-74C1BFC7E5B7Q38188862-F17F02CC-0C2B-4C0F-924A-D5246CE03A52Q38216654-C2810B09-AF2C-4D89-8A3C-C282E581D63EQ38251801-7399917C-FF9A-48C6-BB19-4E119B72C422Q38912240-CC733715-C014-4EB4-9A1A-5AD94E9024F0Q41160241-C372E8D8-B84F-43C6-95C7-0BC3543F3C53Q48005178-7A8BE96A-3C5D-4636-9BEF-F2FA0231E5DAQ55631301-63770E1B-FA8E-4E0C-B57E-2CFDF5544BB2
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Targeting the Jak/STAT pathway for immunosuppression.
@ast
Targeting the Jak/STAT pathway for immunosuppression.
@en
type
label
Targeting the Jak/STAT pathway for immunosuppression.
@ast
Targeting the Jak/STAT pathway for immunosuppression.
@en
prefLabel
Targeting the Jak/STAT pathway for immunosuppression.
@ast
Targeting the Jak/STAT pathway for immunosuppression.
@en
P2860
P356
P1476
Targeting the Jak/STAT pathway for immunosuppression.
@en
P2093
J J O'shea
P2860
P304
P356
10.1136/ARD.2004.028290
P407
P478
63 Suppl 2
P577
2004-11-01T00:00:00Z